Intellipharmaceutics International Inc. (IPCIF)
USD 0.15
(N/A%)
USD 0.15
(N/A%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.43 Million USD | 0.0% |
| 2022 | 1.43 Million USD | -31.69% |
| 2021 | 2.09 Million USD | -38.1% |
| 2020 | 3.38 Million USD | -70.48% |
| 2019 | 11.47 Million USD | 55.12% |
| 2018 | 7.39 Million USD | -7.25% |
| 2017 | 7.97 Million USD | 52.65% |
| 2016 | 5.22 Million USD | -33.66% |
| 2015 | 7.87 Million USD | 79.82% |
| 2014 | 4.37 Million USD | 76.96% |
| 2013 | 2.47 Million USD | -60.38% |
| 2012 | 6.24 Million USD | 91.18% |
| 2011 | 3.26 Million USD | -70.51% |
| 2010 | 11.08 Million USD | 47.31% |
| 2009 | 7.52 Million USD | -73.17% |
| 2008 | 28.03 Million USD | -23.38% |
| 2007 | 36.59 Million USD | -54.92% |
| 2006 | 81.17 Million USD | 19.05% |
| 2005 | 68.18 Million USD | 28.67% |
| 2004 | 52.99 Million USD | 69.81% |
| 2003 | 31.2 Million USD | 10.34% |
| 2002 | 28.28 Million USD | -3.17% |
| 2001 | 29.2 Million USD | 279.09% |
| 2000 | 7.7 Million USD | 57.49% |
| 1999 | 4.89 Million USD | -37.28% |
| 1998 | 7.8 Million USD | 15.51% |
| 1997 | 6.75 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.73 Million USD | 8.77% |
| 2024 Q3 | 1.56 Million USD | -9.77% |
| 2024 Q1 | 1.59 Million USD | 11.41% |
| 2023 Q3 | 1.43 Million USD | -23.63% |
| 2023 FY | 1.43 Million USD | 0.0% |
| 2023 Q2 | 1.88 Million USD | -0.42% |
| 2023 Q4 | 1.43 Million USD | -0.35% |
| 2023 Q1 | 1.88 Million USD | -9.87% |
| 2022 FY | 1.43 Million USD | -31.69% |
| 2022 Q1 | 2.68 Million USD | -20.79% |
| 2022 Q2 | 4.97 Million USD | 85.56% |
| 2022 Q3 | 3.45 Million USD | -30.57% |
| 2022 Q4 | 2.09 Million USD | -39.35% |
| 2021 Q1 | 3.6 Million USD | -5.09% |
| 2021 Q4 | 3.38 Million USD | -19.69% |
| 2021 Q2 | 3.56 Million USD | -1.12% |
| 2021 Q3 | 4.21 Million USD | 18.35% |
| 2021 FY | 2.09 Million USD | -38.1% |
| 2020 Q1 | 7.55 Million USD | -34.18% |
| 2020 FY | 3.38 Million USD | -70.48% |
| 2020 Q2 | 5.56 Million USD | -26.28% |
| 2020 Q3 | 4.16 Million USD | -25.23% |
| 2020 Q4 | 3.79 Million USD | -8.79% |
| 2019 FY | 11.47 Million USD | 55.12% |
| 2019 Q4 | 11.47 Million USD | 103.66% |
| 2019 Q2 | 6.66 Million USD | 23.67% |
| 2019 Q3 | 5.63 Million USD | -15.51% |
| 2019 Q1 | 5.39 Million USD | -27.1% |
| 2018 Q1 | 7.95 Million USD | -0.19% |
| 2018 FY | 7.39 Million USD | -7.25% |
| 2018 Q4 | 7.39 Million USD | 11.09% |
| 2018 Q3 | 6.65 Million USD | -14.41% |
| 2018 Q2 | 7.77 Million USD | -2.26% |
| 2017 Q3 | 5.36 Million USD | 40.55% |
| 2017 FY | 7.97 Million USD | 52.65% |
| 2017 Q1 | 3.81 Million USD | -26.99% |
| 2017 Q2 | 3.81 Million USD | 0.13% |
| 2017 Q4 | 7.97 Million USD | 48.57% |
| 2016 FY | 5.22 Million USD | -33.66% |
| 2016 Q2 | 6.64 Million USD | -9.2% |
| 2016 Q1 | 7.31 Million USD | -7.11% |
| 2016 Q3 | 6.21 Million USD | -6.37% |
| 2016 Q4 | 5.22 Million USD | -16.0% |
| 2015 Q4 | 7.87 Million USD | -12.65% |
| 2015 Q1 | 10.45 Million USD | 138.71% |
| 2015 Q2 | 11 Million USD | 5.22% |
| 2015 Q3 | 9.01 Million USD | -18.04% |
| 2015 FY | 7.87 Million USD | 79.82% |
| 2014 Q2 | 3.6 Million USD | 41.45% |
| 2014 Q1 | 2.55 Million USD | 3.06% |
| 2014 Q3 | 4.11 Million USD | 14.01% |
| 2014 FY | 4.37 Million USD | 76.96% |
| 2014 Q4 | 4.37 Million USD | 6.47% |
| 2013 Q1 | 4.4 Million USD | -29.54% |
| 2013 Q2 | 6.91 Million USD | 57.05% |
| 2013 FY | 2.47 Million USD | -60.38% |
| 2013 Q3 | 4.95 Million USD | -28.35% |
| 2013 Q4 | 2.47 Million USD | -50.03% |
| 2012 Q2 | 10.55 Million USD | -14.45% |
| 2012 Q3 | 9.02 Million USD | -14.51% |
| 2012 Q4 | 6.24 Million USD | -30.78% |
| 2012 FY | 6.24 Million USD | 91.18% |
| 2012 Q1 | 12.34 Million USD | 277.67% |
| 2011 FY | 3.26 Million USD | -70.51% |
| 2011 Q2 | 6.39 Million USD | -20.91% |
| 2011 Q4 | 3.26 Million USD | -29.18% |
| 2011 Q3 | 4.61 Million USD | -27.8% |
| 2011 Q1 | 8.08 Million USD | -27.07% |
| 2010 Q1 | 6.13 Million USD | -18.39% |
| 2010 Q2 | 6.12 Million USD | -0.31% |
| 2010 Q3 | 5.12 Million USD | -16.32% |
| 2010 Q4 | 11.08 Million USD | 116.38% |
| 2010 FY | 11.08 Million USD | 47.31% |
| 2009 Q4 | 7.52 Million USD | -25.09% |
| 2009 Q1 | 23.35 Million USD | -16.7% |
| 2009 Q2 | 13.78 Million USD | -40.99% |
| 2009 Q3 | 10.04 Million USD | -27.13% |
| 2009 FY | 7.52 Million USD | -73.17% |
| 2008 Q4 | 28.03 Million USD | -9.82% |
| 2008 FY | 28.03 Million USD | -23.38% |
| 2008 Q3 | 31.08 Million USD | -12.01% |
| 2008 Q2 | 35.33 Million USD | 30.46% |
| 2008 Q1 | 27.08 Million USD | -25.99% |
| 2007 Q1 | 60.45 Million USD | -25.52% |
| 2007 Q2 | 44.43 Million USD | -26.5% |
| 2007 Q3 | 27.69 Million USD | -37.68% |
| 2007 Q4 | 36.59 Million USD | 32.13% |
| 2007 FY | 36.59 Million USD | -54.92% |
| 2006 Q3 | 59.8 Million USD | -18.6% |
| 2006 FY | 81.17 Million USD | 19.05% |
| 2006 Q2 | 73.47 Million USD | -18.63% |
| 2006 Q1 | 90.3 Million USD | 32.44% |
| 2006 Q4 | 81.17 Million USD | 35.73% |
| 2005 FY | 68.18 Million USD | 28.67% |
| 2005 Q4 | 68.18 Million USD | -8.34% |
| 2005 Q3 | 74.39 Million USD | -11.48% |
| 2005 Q2 | 84.03 Million USD | 94.21% |
| 2005 Q1 | 43.27 Million USD | -18.34% |
| 2004 Q3 | 56.12 Million USD | 112.0% |
| 2004 Q2 | 26.47 Million USD | -7.53% |
| 2004 Q1 | 28.63 Million USD | -8.26% |
| 2004 FY | 52.99 Million USD | 69.81% |
| 2004 Q4 | 52.99 Million USD | -5.59% |
| 2003 Q4 | 31.2 Million USD | -7.94% |
| 2003 Q3 | 33.89 Million USD | -9.36% |
| 2003 Q2 | 37.4 Million USD | 49.08% |
| 2003 Q1 | 25.08 Million USD | -11.29% |
| 2003 FY | 31.2 Million USD | 10.34% |
| 2002 Q1 | 27.46 Million USD | -5.96% |
| 2002 Q2 | 25.02 Million USD | -8.88% |
| 2002 Q3 | 22.67 Million USD | -9.41% |
| 2002 Q4 | 28.28 Million USD | 24.75% |
| 2002 FY | 28.28 Million USD | -3.17% |
| 2001 Q3 | 30.75 Million USD | 63.4% |
| 2001 FY | 29.2 Million USD | 279.09% |
| 2001 Q1 | 19.93 Million USD | 158.76% |
| 2001 Q2 | 18.81 Million USD | -5.6% |
| 2001 Q4 | 29.2 Million USD | -5.03% |
| 2000 Q4 | 7.7 Million USD | 0.19% |
| 2000 FY | 7.7 Million USD | 57.49% |
| 2000 Q1 | 9.71 Million USD | 98.49% |
| 2000 Q3 | 7.68 Million USD | -13.36% |
| 2000 Q2 | 8.87 Million USD | -8.6% |
| 1999 Q3 | 6.77 Million USD | -21.73% |
| 1999 Q2 | 8.65 Million USD | 32.38% |
| 1999 Q1 | 6.53 Million USD | -16.23% |
| 1999 Q4 | 4.89 Million USD | -27.74% |
| 1999 FY | 4.89 Million USD | -37.28% |
| 1998 FY | 7.8 Million USD | 15.51% |
| 1998 Q1 | 7.89 Million USD | 0.0% |
| 1998 Q2 | 6.74 Million USD | -14.49% |
| 1998 Q3 | 9.35 Million USD | 38.7% |
| 1998 Q4 | 7.8 Million USD | -16.66% |
| 1997 FY | 6.75 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -61892.727% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 26.87% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 86.431% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -159.37% |
| Rebus Holdings, Inc. | 5000.00 USD | -28540.64% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 98.9% |
| Qrons Inc. | 420.00 USD | -340860.0% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -85.823% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 94.875% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -197.994% |
| Skye Bioscience, Inc. | 11.94 Million USD | 88.007% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 96.314% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 80.165% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -1775.517% |
| SQZ Biotechnologies Company | 107.18 Million USD | 98.664% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -1878.901% |
| Mesoblast Limited | 667.9 Million USD | 99.786% |
| Marizyme, Inc. | 22.01 Million USD | 93.495% |
| Genus plc | 1.02 Billion USD | 99.861% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -5.424% |
| Pharming Group N.V. | 462.85 Million USD | 99.691% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 56.776% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -186.958% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -128.394% |
| ContraFect Corporation | 20.67 Million USD | 93.075% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -266.843% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -274.704% |
| IMV Inc. | 31.33 Million USD | 95.43% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 65.46% |
| MultiCell Technologies, Inc. | 126.22 USD | -1134452.369% |
| ONE Bio Corp. | 70.08 Million USD | 97.957% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -52.394% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 98.886% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -231.708% |
| Q BioMed Inc. | 3.51 Million USD | 59.265% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 95.929% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -448.09% |
| Biomind Labs Inc. | 73.81 Thousand USD | -1839.923% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.679% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 1.16% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 95.229% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 47.857% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -108.3% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 44.989% |
| GB Sciences, Inc. | 103.44 Thousand USD | -1284.382% |
| Alpha Cognition Inc. | 2.45 Million USD | 41.601% |
| HST Global, Inc. | 1526.00 USD | -93742.202% |
| CSL Limited | 38.02 Billion USD | 99.996% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -44.947% |
| Halberd Corporation | 10.13 Thousand USD | -14035.15% |
| Enzolytics Inc. | 361.7 Million USD | 99.604% |
| Agentix Corp. | 261.39 Thousand USD | -447.848% |
| Resverlogix Corp. | 8.11 Million USD | 82.353% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 23.742% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.968% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 96.998% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -123.875% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -6186.081% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 83.998% |
| AVAX Technologies, Inc. | 7.37 Million USD | 80.588% |
| Zenith Capital Corp. | 7410.00 USD | -19225.668% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.958% |
| Ember Therapeutics, Inc. | 184.00 USD | -778178.261% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -344.999% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -447.907% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -54.32% |
| Kadimastem Ltd | 2.3 Million USD | 37.848% |
| Helix BioMedix, Inc. | 3.02 Million USD | 52.661% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 97.283% |
| BioStem Technologies, Inc. | 14.56 Million USD | 90.165% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -2408.201% |
| LadRx Corporation | 2.3 Million USD | 37.95% |
| Cell Source, Inc. | 195.17 Thousand USD | -633.732% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -304.967% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -304.967% |
| NovAccess Global Inc. | 62.24 Thousand USD | -2200.527% |
| Affymax, Inc. | 7.44 Million USD | 80.76% |
| Itoco Inc. | 1.4 Million USD | -2.283% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -1397.049% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -1250.974% |
| Mobile Lads Corp. | 52.00 USD | -2753807.692% |
| CytoDyn Inc. | 11.13 Million USD | 87.141% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -901.617% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -7909.128% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -271.502% |
| SYBLEU INC | 330.46 Thousand USD | -333.335% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -249.769% |
| International Stem Cell Corporation | 5.39 Million USD | 73.432% |
| Bioxytran, Inc. | 137.63 Thousand USD | -940.434% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 90.454% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 91.362% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -1712.699% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -65.615% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 80.949% |
| Neutra Corp. | 2851.00 USD | -50129.113% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 95.581% |
| PureTech Health plc | 693.97 Million USD | 99.794% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 82.257% |
| IXICO plc | 15.84 Million USD | 90.962% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 82.709% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.614% |
| CSL Limited | 38.02 Billion USD | 99.996% |
| Cellectis S.A. | 333.99 Million USD | 99.571% |